Grace Therapeutics, Inc.GRCE
Key ratios
ROA
-10.0%2026
2025
-14.4%2024
-9.3%
ROE
-11.9%2026
2025
-14.9%2024
-19.8%
Recent news
Grace Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
Grace Therapeutics Announces $10 Million Private Placement
Track GRCE in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer